Replies to post #150346 on Biotech Values

[genisi]

Obviously the purpose of the GALA trial was to show that the thrice-weekly 40mg formulation's efficacy and safety are in the same ballpark as the 'known' profile of regular daily Copaxone, with emphasis on the convenience benefit. That's what they need to file. Converting patients is harder but as long as there's no generic version...